Skip to main content
. 2020 Jun 17;8(8):2592–2599.e3. doi: 10.1016/j.jaip.2020.06.001

Table E4.

Pediatric patients with asthma reviewed by the participating centers, in the past and during the COVID-19 pandemic

Patients reviewed Overall cohort COVID-19 burden (deaths/million)
Clinical setting
<10 10-100 >100 Primary Secondary Tertiary
No. of consultations per respondent per week, median (IQR) 20 (10-25) 12.5 (5-20) 18 (14-28) 20 (10-25) 20 (10-25) 5 (5-10) 20 (11-24)
 No. of participants contributing data, N 61 22 10 23 13 9 34
 Total no. of patients evaluated weekly by respondents, N 1,727 326 301 785 292 69 1081
 Annualized estimate of patients evaluated, N 89,804 16,952 15,652 40,820 15,184 3,588 56,212
No. of patients evaluated per respondent during the preceding month, median (IQR) 35 (20-60) 25 (10-40) 38 (21-60) 48 (20-68) 50 (10-100) 25 (10-30) 40 (20-60)
 No. of participants contributing data, N 59 22 14 22 13 9 37
 Total no. of patients evaluated during the preceding month by participants, N 3,593 820 728 1,925 870 214 2,509
 Annualized estimate of patients evaluated, N 43,116 9,840 8,736 23,100 10,440 2,568 30,108
No. of new patients per respondent per week, during COVID-19, median (IQR) 5 (3-9) 3.5 (2-5) 4 (3-6) 5 (3-10) 5 (2-8) 4 (4-5) 5 (3-10)
 No. of participants contributing data, N 27 10 4 9 8 2 14
 Total no., N 194 63 20 74 62 8 97
No. of patients receiving biologics in the clinic, median (IQR) 11 (5-20) 5 (3-10) 9 (5-15) 20 (10-30) 10 (5-17) 3 (3-3) 11 (6-20)
 No. of participants contributing data, N 38 8 9 20 4 1 32